Concepedia

Elyssa Ott

EO

Statistics

Publications

9

Citations

693

H-Index

9

Active since

2005

Affiliations

Janssen Scientific Affairs (United States)(Current)

Janssen (United States)

Icahn School of Medicine at Mount Sinai

Probity Medical Research

Weill Cornell Medicine

Elyssa Ott is an author at Janssen Scientific Affairs (United States) specializing in pharmacotherapy, clinical pharmacology, and medicine.

Publications per year

2005–2024

9

Publications

9

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

Arie Katz, Chandrasekhar Udata, Elyssa Ott et al. · The Journal of Clinical Pharmacology · 2009 · 206 citations

Medicine, Pharmacokinetics, Pharmacology +16

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Subrata Ghosh, Lianne S. Gensler, Zijiang Yang et al. · Drug Safety · 2019 · 116 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

William J. Sandborn, Brian G. Feagan, Silvio Danese et al. · Inflammatory Bowel Diseases · 2020 · 115 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

Kristian Reich, Kim Papp, C.E.M. Griffiths et al. · PubMed · 2012 · 74 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A Randomized Trial Assessing Dorzolamide in Patients With Glaucoma Who Are Younger Than 6 Years

Elyssa Ott · Archives of Ophthalmology · 2005 · 57 citations

Medicine, Ophthalmology, Pharmacotherapy +16

1–5 of 9